Australian researchers report findings from a national, real-world trial of a fingerstick test for hepatitis B DNA, designed for use in clinics without full laboratory facilities. The study suggests the fingerstick hepatitis B test can deliver results within about an hour and may be performed in decentralised settings—from remote communities to routine GP clinics—potentially widening access to diagnosis for people who face barriers to traditional lab testing. The technology aims to simplify screening, reduce the time from testing to treatment decisions, and improve linkage to care for people with suspected infection. If adopted at scale, it could complement vaccination and treatment programs by making it easier to identify active infections in settings where access to high-complexity laboratory infrastructure is limited.
What we know
- Rapid results within about an hour, enabling quicker clinical decisions across diverse care settings.
- Decentralised use showcases the potential to operate in clinics that do not rely on central laboratories.
- Comparable accuracy to standard lab assays for detecting hepatitis B DNA in the trial context.
- Improved access aligns with efforts to expand hepatitis B screening in resource-limited regions and populations with limited healthcare access.
- Publication milestone the findings appeared in a peer-reviewed microbiology journal, signaling a milestone for point-of-care molecular testing in infectious disease.
What we don’t know
- The durability of performance when the test is rolled out broadly across diverse populations and real-world settings remains to be proven.
- Cost per test, required equipment, and ongoing maintenance requirements are not yet defined for large-scale use.
- Regulatory approval timelines and how quickly health systems could integrate the test into routine practice are unclear.
- Operational needs such as training, quality control, and data management for decentralised clinics will require careful planning.
- Whether confirmatory testing or additional monitoring would be needed in specific clinical scenarios is not yet established.
Health professionals emphasise that while the early results are encouraging, the path to widespread adoption will depend on evidence from broader implementation, cost considerations, and clear guidelines for integration into existing care pathways. The concept fits within broader public health aims to accelerate hepatitis B diagnosis, improve patient outcomes, and reduce transmission, but policymakers will be watching for long-term data on real-world impact and sustainability.
